| Literature DB >> 30857352 |
Aoyu Li1,2,3,4, Huahua Yu5,6,7, Rongfeng Li8,9,10, Song Liu11,12,13, Ronge Xing14,15,16, Pengcheng Li17,18,19.
Abstract
Jellyfish envenomations result in extensive dermatological symptoms, clinically named as jellyfish dermatitis, which can seriously affect the daily activities and physical health of people. Inflammatory response accompanies the whole process of jellyfish dermatitis and the complexity of jellyfish venom components makes it difficult to treat jellyfish dermatitis symptoms effectively. Moreover, inhibiting inflammation is essential for the treatment of jellyfish stings and exploring the main components of jellyfish venom that cause inflammation is an urgent research area. In this study, the inhibitory effects of matrix metalloproteinase (MMP) inhibitors for venom-induced inflammation were explored at a cellular level. The expression of the three inflammatory factors, IL-6, TNF-α and MCP-1 in two skin cell lines, human keratinocyte cells (HaCaT) and human embryonic skin fibroblasts cells (CCC-ESF-1), at the cellular level, after treatment with the inhibitors of jellyfish Nemopilema nomurai (N. nomurai) nematocyst venom (NnNV-I), were determined. The results showed that inhibitors of MMP can significantly reduce the toxic effects of jellyfish Nemopilema nomurai nematocyst venom (NnNV) to skin cells. The expression levels of the three inflammatory factors IL-6, MCP-1, and TNF-α in the cells were also significantly decreased, indicating that MMPs in jellyfish venom are probably vital factors leading to jellyfish dermatitis. This study is beneficial in the prevention and treatment of jellyfish stings.Entities:
Keywords: Nemopilema nomurai nematocyst venom (NnNV); inflammatory factors; jellyfish dermatitis; matrix metalloproteinases (MMPs); skin cells
Mesh:
Substances:
Year: 2019 PMID: 30857352 PMCID: PMC6468808 DOI: 10.3390/toxins11030156
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1(A) Effect of Nemopilema nomurai nematocyst venom (NnNV) on the viability of HaCaT and CCC-ESF-1 cells. HaCaT and CCC-ESF-1 cells were treated with various concentrations of NnNV for 24 h and cell viability was measured using the MTT assay. (B) Effect of inhibitors of NnNV (NnNV-I) on the viability of HaCaT and CCC-ESF-1 cell. HaCaT and CCC-ESF-1 cells were treated with the mixture of NnNV (50 μg/mL, final concentration) and BMT (0.5 μM, final concentration) or EDTA (20 μM, final concentration) for 24 h and cell viability was measured with the MTT assay. * p < 0.05, ** p < 0.005, and *** p < 0.001 vs. Control (to verify the effect of NnNV on cell viability), # p < 0.05, ## p < 0.005, and ### p < 0.001 vs. NnNV (to verify that MMP inhibitors can reduce the inhibition rate of NnNV on cells).
Figure 2Effect of NnNV on the gene expression of IL-6, MCP-1, and TNF-α in HaCaT and CCC-ESF-1 cells at different times. (A–C) HaCaT and (D–F) CCC-ESF-1 were treated with 10 μg/mL NnNV for various times (0, 1, 3, 6, and 12 h). * p < 0.05, ** p < 0.005, and *** p < 0.001 vs. Control.
Figure 3Effect of NnNV and NnNV-I on the gene expression of IL-6, MCP-1 and TNF-α in HaCaT and CCC-ESF-1 cells. (A–C) HaCaT and (D–F) CCC-ESF-1 were treated with various concentrations of NnNV for 24 h. (G–I) HaCaT and (J–L) CCC-ESF-1 were treated with various NnNV-I for 24 h. * p < 0.05, ** p < 0.005 and *** p < 0.001 vs. Control (to verify that NnNV can promote mRNA expression of the inflammatory factors in cells), # p < 0.05, ## p < 0.005 and ### p < 0.001 vs. NnNV (to verify that MMP inhibitors can reduce mRNA expression of the inflammatory factors of NnNV in cells).
Figure 4Effect of NnNV and NnNV-I on the cell protein expression of IL-6, MCP-1 and TNF-α on HaCaT and CCC-ESF-1 cells. (A–C) HaCaT and (D–F) CCC-ESF-1 were treated with various concentrations of NnNV for 24 h. (G–I) HaCaT and (J–L) CCC-ESF-1 were treated with various NnNV-I for 24 h. * p < 0.05, ** p < 0.005, and *** p < 0.001 vs. Control (to verify that NnNV can promote the protein expression of inflammatory factors in cells). # p < 0.05, ## p < 0.005, and ### p < 0.001 vs. NnNV (to verify that MMP inhibitors can reduce the protein expression of inflammatory factors of NnNV in cells).
Primer sequences of IL-6, MCP-1, TNF-α, and β-actin.
| Primer Pairs | |
|---|---|
| β-actin | F: 5′-GGCACCACACCTTCTACAATGAGC-3′ |
| R: 5′-GATAGCACAGCCTGGATAGCAACG-3′ | |
| IL-6 | F: 5′-GTCCAGTTGCCTTCTCCC-3′ |
| R: 5′-GCCTCTTTGCTGCTTTCA-3′ | |
| MCP-1 | F: 5′-CTTCTGTGCCTGCTGCTC-3′ |
| R: 5′-TGCTGCTGGTGATTCTTCT-3′ | |
| TNF-α | F: 5′-CGTGGAGCTGGCCGAGGAG-3′ |
| R: 5′-AGGAAGGAGAAGAGGCTGAGGAAC-3′ |
F: Forward primer, R: Reversed primer